Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (NASDAQ: APOP) on March 4, 2020, covering the month of March 2020. The filing announces a strategic commercial agreement and a potential merger with Canndoc Ltd., a wholly owned subsidiary of Intercure Ltd.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) for the period. Instead, it details the following transaction-specific financial terms:
- Product Supply Value: Canndoc will supply a minimum of 6 tons of GMP pharma grade cannabis products over five years with a total value of $18 million USD.
- Equity Consideration (Commercial Deal): Cellect will issue 1,023,720 American Depositary Receipts (ADRs) to Canndoc, representing 19% of Cellect's share capital on a partially diluted basis.
- Proposed Merger Structure: Under a non-binding Letter of Intent (LOI), Cellect would acquire all of Canndoc's outstanding shares in exchange for additional ADRs, resulting in Canndoc shareholders holding approximately 95% (93% fully diluted) of the merged entity.
- Liquidity Commitment: Intercure has committed to invest at least $3 million USD in any public offering Cellect may undertake, at a price of not less than $4.50 USD per ADR, to assist in maintaining NASDAQ listing requirements.
Material Changes and Strategic Developments
The primary material change is the entry into a binding commercial LOI and a non-binding merger LOI with Canndoc/Intercure. This represents a significant shift in Cellect's business model toward the reduction of opioid usage using cannabis products. The commercial deal grants Cellect rights to Canndoc's products, data, and clinical trials, with distribution handled by Canndoc's existing channels.
Outlook, Risks, and Contingencies
Outlook: The parties aim to close the proposed merger in the second quarter of 2020. The commercial agreement includes an option to extend for an additional five years until 2029.
Risks and Contingencies:
- The merger is subject to definitive agreements, Board approvals, and customary closing conditions.
- Regulatory approval from the Israeli Medical Cannabis Agency (IMCA) is required.
- Shareholder approval from Cellect is required for the merger.
- The commercial deal is subject to definitive agreements.
Key Facts for Investor Verification
- Verify the status of definitive agreements for both the commercial supply deal and the proposed merger.
- Confirm the timeline for IMCA and Cellect shareholder approvals required for the merger.
- Assess the impact of the 19% equity issuance on existing shareholders and the potential dilution from the proposed 95% merger structure.
- Monitor the execution of Intercure's $3 million investment commitment to ensure NASDAQ listing compliance.